What is the appropriate workup for a patient suspected of having celiac disease and irritable bowel syndrome?

Workup for Suspected Celiac Disease and IBS

For patients with suspected celiac disease and IBS, perform celiac serology testing (tissue transglutaminase-IgA with total IgA) first, followed by duodenal biopsies if positive, while the patient is still consuming gluten—this approach is essential because celiac disease is 4-fold more common in IBS patients and requires definitive diagnosis before dietary intervention. 1, 2

Diagnostic Algorithm

Step 1: Celiac Disease Screening (Mandatory)

• Perform tissue transglutaminase-IgA (TG2-IgA) testing with total IgA level in all patients with IBS-like symptoms 3, 1
• This is particularly critical for IBS-diarrhea subtype 1
• The prevalence of biopsy-proven celiac disease is 4.1% in IBS patients vs. 0.9% in general population 2, 4

Critical caveat: Patient must be consuming gluten at time of testing—reduction or avoidance of gluten prior to testing significantly reduces sensitivity of both serology and biopsy 3

Step 2: Interpret Celiac Serology Results

If TG2-IgA is strongly positive (>10x upper normal limit):

• Confirm with endomysial antibody on second blood sample
• This combination has virtually 100% positive predictive value for celiac disease 3
• Proceed to esophagogastroduodenoscopy (EGD) with duodenal biopsies for confirmation and differential diagnosis 3

If TG2-IgA is negative but total IgA is low/absent:

• IgA deficiency occurs in ~2-3% of celiac patients 3
• Order IgG-based tests: TG2-IgG and IgG deamidated gliadin antibody 3
• Note: IgG isotype testing is NOT specific in absence of IgA deficiency 3

If serology is negative but clinical suspicion remains high:

• Consider repeat biopsies, as negative biopsies don't exclude celiac disease if serology is positive 3
• HLA-DQ2/DQ8 testing has limited diagnostic role but high negative predictive value to rule out celiac disease 3

Step 3: Duodenal Biopsy Evaluation

• Obtain multiple duodenal biopsies (standard practice: ≥4 biopsies from duodenum) 3
• Histological analysis should include:
  • Marsh classification
  • Intraepithelial lymphocyte count per high-power field
  • Morphometry assessment 3

If biopsies show villous atrophy but serology was not obtained:

• Perform celiac-specific serology as confirmatory test before initiating gluten-free diet 3

Step 4: Additional IBS Workup (After Celiac Exclusion)

For IBS-diarrhea subtype:

• Fecal calprotectin to exclude inflammatory bowel disease 1
• Consider colonoscopy with biopsies if:
  • Female sex, age ≥50 years
  • Nocturnal or severe watery diarrhea
  • Weight loss
  • Duration <12 months
  • Autoimmune disease history
  • Use of NSAIDs, PPIs, SSRIs, or statins
  • These factors suggest microscopic colitis 5

For all IBS subtypes:

• Complete blood count
• C-reactive protein or fecal calprotectin
• Age-appropriate colorectal cancer screening 6

Alarm features requiring urgent evaluation:

• Symptom onset after age 50
• Unexplained weight loss
• Family history of GI malignancy, IBD, or celiac disease
• Evidence of GI blood loss
• Unexplained iron-deficiency anemia 5, 6

Key Clinical Pitfalls

Gluten restriction before diagnosis: This is the most common error—patients who have already started gluten-free diet should resume normal diet with three slices of wheat bread daily for 1-3 months before repeat TG2-IgA testing 3

Assuming negative serology excludes celiac disease: In patients with strong clinical suspicion and negative serology, check total IgA levels and consider IgG-based testing 3

Over-reliance on colonoscopy in typical IBS: Colonoscopy yield is extremely low in typical IBS without alarm features and does not provide reassurance to patients 5

Missing the temporal relationship: Celiac disease is associated with IBS diagnosis both before and after celiac diagnosis, with 3-fold increased risk of prior IBS diagnosis 7. This bidirectional relationship suggests shared pathophysiology or diagnostic overlap.

Evidence Strength Considerations

The recommendation to screen for celiac disease in IBS is supported by multiple high-quality guidelines 3, 5, 1 and meta-analyses showing 4-fold increased odds of biopsy-proven celiac disease in IBS patients 2, 4. However, North American studies show inconsistent results 2, suggesting geographic variation in prevalence. Despite this, the 2021 ACG IBS guideline specifically recommends celiac screening in IBS-diarrhea patients 1, and the 2019 AGA celiac guideline provides the most current diagnostic algorithm 3.

The British Society of Gastroenterology 2021 guideline emphasizes that in patients with typical IBS symptoms, normal investigations, and no alarm features, the diagnosis is secure without extensive testing 5—but this assumes celiac disease has already been excluded.